The Long Road: Improving Outcome In Elderly "Unfit" Aml?
BLOOD(2020)
摘要
In this issue of Blood, Wei et al(1) report the results of a prospective randomized placebo-controlled trial that presents formal evidence of an overall survival benefit of adding venetoclax to low-dose cytarabine (LDAC) in elderly patients with newly diagnosed acute myeloid leukemia (AML) not considered eligible for intensive cytotoxic treatment.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络